The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Association of objective response by mRECIST with better overall survival (OS) in patients with advanced hepatocellular carcinoma (HCC) treated with systemic therapies: A systematic review and meta-analysis of randomized controlled trials.
 
Masatoshi Kudo
Honoraria - Bayer; Bayer; Bayer; Bayer; Eisai; Eisai; Eisai; Eisai; MSD; MSD; MSD; MSD
Consulting or Advisory Role - Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Eisai; Eisai; Eisai; Eisai; MSD; MSD; MSD; MSD; Ono Pharmaceutical; Ono Pharmaceutical; Ono Pharmaceutical; Ono Pharmaceutical
Research Funding - Abbvie (Inst); Abbvie (Inst); Abbvie (Inst); Abbvie (Inst); EA Pharma (Inst); EA Pharma (Inst); EA Pharma (Inst); EA Pharma (Inst); Eisai (Inst); Eisai (Inst); Eisai (Inst); Eisai (Inst); Gilead Sciences (Inst); Gilead Sciences (Inst); Gilead Sciences (Inst); Gilead Sciences (Inst); Otsuka (Inst); Otsuka (Inst); Otsuka (Inst); Otsuka (Inst); Taiho Pharmaceutical (Inst); Taiho Pharmaceutical (Inst); Taiho Pharmaceutical (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst); Takeda (Inst); Takeda (Inst); Takeda (Inst)
 
Yasutaka Chiba
Honoraria - Chugai Pharma; Chugai Pharma; Chugai Pharma; Chugai Pharma
 
Tim Meyer
Consulting or Advisory Role - Beigene; Beigene; Beigene; Beigene; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; BTG; BTG; BTG; BTG; Eisai; Eisai; Eisai; Eisai; Ipsen; Ipsen; Ipsen; Ipsen; MSD; MSD; MSD; MSD; Tarveda Therapeutics; Tarveda Therapeutics; Tarveda Therapeutics; Tarveda Therapeutics
Research Funding - Bayer (Inst); Bayer (Inst); Bayer (Inst); Bayer (Inst); BTG (Inst); BTG (Inst); BTG (Inst); BTG (Inst); Ipsen (Inst); Ipsen (Inst); Ipsen (Inst); Ipsen (Inst)
 
Riccardo Lencioni
Consulting or Advisory Role - Celsion; Celsion; Celsion; Celsion; Eisai; Eisai; Eisai; Eisai; Roche/Genentech; Roche/Genentech; Roche/Genentech; Roche/Genentech
Research Funding - AstraZeneca; AstraZeneca; AstraZeneca; AstraZeneca
 
Josep M. Llovet
Consulting or Advisory Role - Bayer; Bayer; Bayer; Bayer; Blueprint Medicines; Blueprint Medicines; Blueprint Medicines; Blueprint Medicines; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Can-Fite BioPharma; Can-Fite BioPharma; Can-Fite BioPharma; Can-Fite BioPharma; Celsion; Celsion; Celsion; Celsion; Eisai; Eisai; Eisai; Eisai; Exelixis; Exelixis; Exelixis; Exelixis; Fortress Biotech; Fortress Biotech; Fortress Biotech; Fortress Biotech; Glycotest; Glycotest; Glycotest; Glycotest; Incyte; Incyte; Incyte; Incyte; Leerink; Leerink; Leerink; Leerink; Lilly; Lilly; Lilly; Lilly; Merck; Merck; Merck; Merck; Midatech Pharma; Midatech Pharma; Midatech Pharma; Midatech Pharma; Navigant Consulting; Navigant Consulting; Navigant Consulting; Navigant Consulting; Nucleix; Nucleix; Nucleix; Nucleix; Spring Bank; Spring Bank; Spring Bank; Spring Bank
Research Funding - Bayer Schering Pharma (Inst); Bayer Schering Pharma (Inst); Bayer Schering Pharma (Inst); Bayer Schering Pharma (Inst); Boehringer Ingelheim (Inst); Boehringer Ingelheim (Inst); Boehringer Ingelheim (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Eisai (Inst); Eisai (Inst); Eisai (Inst); Eisai (Inst); Ipsen (Inst); Ipsen (Inst); Ipsen (Inst); Ipsen (Inst)
Travel, Accommodations, Expenses - Bayer; Bayer; Bayer; Bayer